nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—EGFR—Vandetanib—thyroid cancer	0.5	0.614	CbGbCtD
Lidocaine—CYP3A7—Sorafenib—thyroid cancer	0.0368	0.0452	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.0368	0.0452	CbGbCtD
Lidocaine—CYP2B6—Sorafenib—thyroid cancer	0.035	0.043	CbGbCtD
Lidocaine—CYP3A5—Sorafenib—thyroid cancer	0.0276	0.0339	CbGbCtD
Lidocaine—CYP2C8—Sorafenib—thyroid cancer	0.0265	0.0326	CbGbCtD
Lidocaine—CYP2B6—Doxorubicin—thyroid cancer	0.0212	0.0261	CbGbCtD
Lidocaine—CYP1A2—Sorafenib—thyroid cancer	0.0205	0.0252	CbGbCtD
Lidocaine—CYP2C9—Sorafenib—thyroid cancer	0.0185	0.0227	CbGbCtD
Lidocaine—ABCB1—Sorafenib—thyroid cancer	0.018	0.0221	CbGbCtD
Lidocaine—CYP3A4—Vandetanib—thyroid cancer	0.0178	0.0219	CbGbCtD
Lidocaine—CYP2D6—Sorafenib—thyroid cancer	0.0169	0.0208	CbGbCtD
Lidocaine—ABCB1—Doxorubicin—thyroid cancer	0.0109	0.0134	CbGbCtD
Lidocaine—CYP3A4—Sorafenib—thyroid cancer	0.0108	0.0132	CbGbCtD
Lidocaine—CYP2D6—Doxorubicin—thyroid cancer	0.0103	0.0126	CbGbCtD
Lidocaine—CYP3A4—Doxorubicin—thyroid cancer	0.00653	0.00802	CbGbCtD
Lidocaine—Respiratory arrest—Vandetanib—thyroid cancer	0.00473	0.0433	CcSEcCtD
Lidocaine—Hoarseness—Sorafenib—thyroid cancer	0.00319	0.0292	CcSEcCtD
Lidocaine—Depressed level of consciousness—Vandetanib—thyroid cancer	0.00201	0.0184	CcSEcCtD
Lidocaine—Oropharyngeal discomfort—Sorafenib—thyroid cancer	0.00193	0.0177	CcSEcCtD
Lidocaine—Dysphonia—Sorafenib—thyroid cancer	0.00171	0.0156	CcSEcCtD
Lidocaine—Dermatitis bullous—Vandetanib—thyroid cancer	0.00158	0.0145	CcSEcCtD
Lidocaine—Cardiac arrest—Vandetanib—thyroid cancer	0.00144	0.0131	CcSEcCtD
Lidocaine—Skin exfoliation—Sorafenib—thyroid cancer	0.00134	0.0123	CcSEcCtD
Lidocaine—Neurotoxicity—Epirubicin—thyroid cancer	0.00134	0.0122	CcSEcCtD
Lidocaine—Neuropathy—Sorafenib—thyroid cancer	0.00132	0.0121	CcSEcCtD
Lidocaine—Dysphagia—Vandetanib—thyroid cancer	0.00131	0.0119	CcSEcCtD
Lidocaine—Bronchospasm—Vandetanib—thyroid cancer	0.00129	0.0117	CcSEcCtD
Lidocaine—Neurotoxicity—Doxorubicin—thyroid cancer	0.00124	0.0113	CcSEcCtD
Lidocaine—Leukoderma—Epirubicin—thyroid cancer	0.00122	0.0112	CcSEcCtD
Lidocaine—Stomatitis—Vandetanib—thyroid cancer	0.00114	0.0104	CcSEcCtD
Lidocaine—Leukoderma—Doxorubicin—thyroid cancer	0.00113	0.0103	CcSEcCtD
Lidocaine—Bradycardia—Vandetanib—thyroid cancer	0.00106	0.00973	CcSEcCtD
Lidocaine—Haemoglobin—Vandetanib—thyroid cancer	0.00105	0.00961	CcSEcCtD
Lidocaine—Haemorrhage—Vandetanib—thyroid cancer	0.00105	0.00956	CcSEcCtD
Lidocaine—Visual impairment—Vandetanib—thyroid cancer	0.00101	0.00921	CcSEcCtD
Lidocaine—Eye disorder—Vandetanib—thyroid cancer	0.000977	0.00893	CcSEcCtD
Lidocaine—Cardiac disorder—Vandetanib—thyroid cancer	0.000971	0.00887	CcSEcCtD
Lidocaine—Angiopathy—Vandetanib—thyroid cancer	0.000949	0.00867	CcSEcCtD
Lidocaine—Local reaction—Epirubicin—thyroid cancer	0.000938	0.00857	CcSEcCtD
Lidocaine—Dysgeusia—Vandetanib—thyroid cancer	0.000891	0.00815	CcSEcCtD
Lidocaine—Dysphagia—Sorafenib—thyroid cancer	0.000881	0.00805	CcSEcCtD
Lidocaine—Local reaction—Doxorubicin—thyroid cancer	0.000868	0.00793	CcSEcCtD
Lidocaine—Vision blurred—Vandetanib—thyroid cancer	0.000858	0.00784	CcSEcCtD
Lidocaine—Tremor—Vandetanib—thyroid cancer	0.000853	0.00779	CcSEcCtD
Lidocaine—Loss of consciousness—Vandetanib—thyroid cancer	0.0008	0.00731	CcSEcCtD
Lidocaine—Convulsion—Vandetanib—thyroid cancer	0.000789	0.00721	CcSEcCtD
Lidocaine—Hypertension—Vandetanib—thyroid cancer	0.000786	0.00718	CcSEcCtD
Lidocaine—Chest pain—Vandetanib—thyroid cancer	0.000775	0.00708	CcSEcCtD
Lidocaine—Anxiety—Vandetanib—thyroid cancer	0.000772	0.00706	CcSEcCtD
Lidocaine—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00077	0.00704	CcSEcCtD
Lidocaine—Redness—Epirubicin—thyroid cancer	0.000769	0.00703	CcSEcCtD
Lidocaine—Stomatitis—Sorafenib—thyroid cancer	0.000766	0.007	CcSEcCtD
Lidocaine—Burning sensation—Epirubicin—thyroid cancer	0.000747	0.00683	CcSEcCtD
Lidocaine—Paralysis—Epirubicin—thyroid cancer	0.000747	0.00683	CcSEcCtD
Lidocaine—Oedema—Vandetanib—thyroid cancer	0.000743	0.00679	CcSEcCtD
Lidocaine—Nervous system disorder—Vandetanib—thyroid cancer	0.000729	0.00666	CcSEcCtD
Lidocaine—Blister—Epirubicin—thyroid cancer	0.00072	0.00658	CcSEcCtD
Lidocaine—Redness—Doxorubicin—thyroid cancer	0.000712	0.0065	CcSEcCtD
Lidocaine—Haemoglobin—Sorafenib—thyroid cancer	0.000709	0.00648	CcSEcCtD
Lidocaine—Haemorrhage—Sorafenib—thyroid cancer	0.000705	0.00645	CcSEcCtD
Lidocaine—Burning sensation—Doxorubicin—thyroid cancer	0.000691	0.00632	CcSEcCtD
Lidocaine—Paralysis—Doxorubicin—thyroid cancer	0.000691	0.00632	CcSEcCtD
Lidocaine—Paraesthesia—Vandetanib—thyroid cancer	0.000667	0.0061	CcSEcCtD
Lidocaine—Blister—Doxorubicin—thyroid cancer	0.000666	0.00609	CcSEcCtD
Lidocaine—Dyspnoea—Vandetanib—thyroid cancer	0.000662	0.00605	CcSEcCtD
Lidocaine—Hyperaesthesia—Epirubicin—thyroid cancer	0.000661	0.00604	CcSEcCtD
Lidocaine—Feeling hot—Epirubicin—thyroid cancer	0.000661	0.00604	CcSEcCtD
Lidocaine—Gingivitis—Epirubicin—thyroid cancer	0.000661	0.00604	CcSEcCtD
Lidocaine—Tinnitus—Sorafenib—thyroid cancer	0.000658	0.00601	CcSEcCtD
Lidocaine—Flushing—Sorafenib—thyroid cancer	0.000655	0.00598	CcSEcCtD
Lidocaine—Cardiac disorder—Sorafenib—thyroid cancer	0.000655	0.00598	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000641	0.00586	CcSEcCtD
Lidocaine—Angiopathy—Sorafenib—thyroid cancer	0.00064	0.00585	CcSEcCtD
Lidocaine—Immune system disorder—Sorafenib—thyroid cancer	0.000637	0.00582	CcSEcCtD
Lidocaine—Pain—Vandetanib—thyroid cancer	0.000635	0.00581	CcSEcCtD
Lidocaine—Petechiae—Epirubicin—thyroid cancer	0.000631	0.00577	CcSEcCtD
Lidocaine—Dysphonia—Epirubicin—thyroid cancer	0.000631	0.00577	CcSEcCtD
Lidocaine—Erythema—Sorafenib—thyroid cancer	0.000614	0.00561	CcSEcCtD
Lidocaine—Hyperaesthesia—Doxorubicin—thyroid cancer	0.000612	0.00559	CcSEcCtD
Lidocaine—Feeling hot—Doxorubicin—thyroid cancer	0.000612	0.00559	CcSEcCtD
Lidocaine—Gingivitis—Doxorubicin—thyroid cancer	0.000612	0.00559	CcSEcCtD
Lidocaine—Dysgeusia—Sorafenib—thyroid cancer	0.000601	0.0055	CcSEcCtD
Lidocaine—Petechiae—Doxorubicin—thyroid cancer	0.000584	0.00534	CcSEcCtD
Lidocaine—Dysphonia—Doxorubicin—thyroid cancer	0.000584	0.00534	CcSEcCtD
Lidocaine—Angioedema—Sorafenib—thyroid cancer	0.000561	0.00513	CcSEcCtD
Lidocaine—Dysarthria—Epirubicin—thyroid cancer	0.000549	0.00502	CcSEcCtD
Lidocaine—Loss of consciousness—Sorafenib—thyroid cancer	0.00054	0.00493	CcSEcCtD
Lidocaine—Atrioventricular block—Epirubicin—thyroid cancer	0.000535	0.00489	CcSEcCtD
Lidocaine—Asthenia—Vandetanib—thyroid cancer	0.000533	0.00487	CcSEcCtD
Lidocaine—Hypertension—Sorafenib—thyroid cancer	0.00053	0.00485	CcSEcCtD
Lidocaine—Ventricular tachycardia—Epirubicin—thyroid cancer	0.000519	0.00474	CcSEcCtD
Lidocaine—Dermatitis contact—Epirubicin—thyroid cancer	0.000513	0.00469	CcSEcCtD
Lidocaine—Dysarthria—Doxorubicin—thyroid cancer	0.000508	0.00464	CcSEcCtD
Lidocaine—Anaphylactic shock—Sorafenib—thyroid cancer	0.000501	0.00458	CcSEcCtD
Lidocaine—Skin exfoliation—Epirubicin—thyroid cancer	0.000496	0.00453	CcSEcCtD
Lidocaine—Atrioventricular block—Doxorubicin—thyroid cancer	0.000495	0.00453	CcSEcCtD
Lidocaine—Shock—Sorafenib—thyroid cancer	0.000493	0.00451	CcSEcCtD
Lidocaine—Nervous system disorder—Sorafenib—thyroid cancer	0.000492	0.00449	CcSEcCtD
Lidocaine—Dizziness—Vandetanib—thyroid cancer	0.000491	0.00449	CcSEcCtD
Lidocaine—Neuropathy—Epirubicin—thyroid cancer	0.000487	0.00445	CcSEcCtD
Lidocaine—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.00048	0.00439	CcSEcCtD
Lidocaine—Dermatitis contact—Doxorubicin—thyroid cancer	0.000475	0.00434	CcSEcCtD
Lidocaine—Coma—Epirubicin—thyroid cancer	0.000474	0.00434	CcSEcCtD
Lidocaine—Vomiting—Vandetanib—thyroid cancer	0.000472	0.00432	CcSEcCtD
Lidocaine—Rash—Vandetanib—thyroid cancer	0.000468	0.00428	CcSEcCtD
Lidocaine—Dermatitis—Vandetanib—thyroid cancer	0.000468	0.00428	CcSEcCtD
Lidocaine—Headache—Vandetanib—thyroid cancer	0.000465	0.00425	CcSEcCtD
Lidocaine—Skin exfoliation—Doxorubicin—thyroid cancer	0.000459	0.00419	CcSEcCtD
Lidocaine—Neuropathy—Doxorubicin—thyroid cancer	0.000451	0.00412	CcSEcCtD
Lidocaine—Dyspnoea—Sorafenib—thyroid cancer	0.000447	0.00408	CcSEcCtD
Lidocaine—Nausea—Vandetanib—thyroid cancer	0.000441	0.00403	CcSEcCtD
Lidocaine—Coma—Doxorubicin—thyroid cancer	0.000439	0.00401	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000433	0.00395	CcSEcCtD
Lidocaine—Pain—Sorafenib—thyroid cancer	0.000429	0.00392	CcSEcCtD
Lidocaine—Urticaria—Sorafenib—thyroid cancer	0.000398	0.00364	CcSEcCtD
Lidocaine—Dermatitis bullous—Epirubicin—thyroid cancer	0.000394	0.0036	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000389	0.00356	CcSEcCtD
Lidocaine—Diplopia—Epirubicin—thyroid cancer	0.000377	0.00344	CcSEcCtD
Lidocaine—Osteoarthritis—Epirubicin—thyroid cancer	0.000377	0.00344	CcSEcCtD
Lidocaine—Hypersensitivity—Sorafenib—thyroid cancer	0.000369	0.00337	CcSEcCtD
Lidocaine—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000365	0.00333	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.00036	0.00329	CcSEcCtD
Lidocaine—Asthenia—Sorafenib—thyroid cancer	0.00036	0.00329	CcSEcCtD
Lidocaine—Cardiac arrest—Epirubicin—thyroid cancer	0.000358	0.00327	CcSEcCtD
Lidocaine—Osteoarthritis—Doxorubicin—thyroid cancer	0.000349	0.00319	CcSEcCtD
Lidocaine—Diplopia—Doxorubicin—thyroid cancer	0.000349	0.00319	CcSEcCtD
Lidocaine—Cardiac arrest—Doxorubicin—thyroid cancer	0.000332	0.00303	CcSEcCtD
Lidocaine—Dizziness—Sorafenib—thyroid cancer	0.000331	0.00303	CcSEcCtD
Lidocaine—Asthma—Epirubicin—thyroid cancer	0.000326	0.00298	CcSEcCtD
Lidocaine—Dysphagia—Epirubicin—thyroid cancer	0.000326	0.00298	CcSEcCtD
Lidocaine—Vomiting—Sorafenib—thyroid cancer	0.000319	0.00291	CcSEcCtD
Lidocaine—Rash—Sorafenib—thyroid cancer	0.000316	0.00289	CcSEcCtD
Lidocaine—Dermatitis—Sorafenib—thyroid cancer	0.000316	0.00289	CcSEcCtD
Lidocaine—Headache—Sorafenib—thyroid cancer	0.000314	0.00287	CcSEcCtD
Lidocaine—Asthma—Doxorubicin—thyroid cancer	0.000301	0.00275	CcSEcCtD
Lidocaine—Dysphagia—Doxorubicin—thyroid cancer	0.000301	0.00275	CcSEcCtD
Lidocaine—Nausea—Sorafenib—thyroid cancer	0.000298	0.00272	CcSEcCtD
Lidocaine—Drowsiness—Epirubicin—thyroid cancer	0.00029	0.00265	CcSEcCtD
Lidocaine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000285	0.0026	CcSEcCtD
Lidocaine—Stomatitis—Epirubicin—thyroid cancer	0.000283	0.00259	CcSEcCtD
Lidocaine—Drowsiness—Doxorubicin—thyroid cancer	0.000269	0.00246	CcSEcCtD
Lidocaine—Bradycardia—Epirubicin—thyroid cancer	0.000265	0.00243	CcSEcCtD
Lidocaine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000263	0.00241	CcSEcCtD
Lidocaine—Haemoglobin—Epirubicin—thyroid cancer	0.000262	0.00239	CcSEcCtD
Lidocaine—Stomatitis—Doxorubicin—thyroid cancer	0.000262	0.00239	CcSEcCtD
Lidocaine—Rhinitis—Epirubicin—thyroid cancer	0.000261	0.00239	CcSEcCtD
Lidocaine—Haemorrhage—Epirubicin—thyroid cancer	0.000261	0.00238	CcSEcCtD
Lidocaine—Hypoaesthesia—Epirubicin—thyroid cancer	0.000259	0.00237	CcSEcCtD
Lidocaine—Visual impairment—Epirubicin—thyroid cancer	0.000251	0.0023	CcSEcCtD
Lidocaine—Bradycardia—Doxorubicin—thyroid cancer	0.000246	0.00224	CcSEcCtD
Lidocaine—Eye disorder—Epirubicin—thyroid cancer	0.000244	0.00223	CcSEcCtD
Lidocaine—Tinnitus—Epirubicin—thyroid cancer	0.000243	0.00222	CcSEcCtD
Lidocaine—Haemoglobin—Doxorubicin—thyroid cancer	0.000242	0.00222	CcSEcCtD
Lidocaine—Cardiac disorder—Epirubicin—thyroid cancer	0.000242	0.00221	CcSEcCtD
Lidocaine—Flushing—Epirubicin—thyroid cancer	0.000242	0.00221	CcSEcCtD
Lidocaine—Rhinitis—Doxorubicin—thyroid cancer	0.000242	0.00221	CcSEcCtD
Lidocaine—Haemorrhage—Doxorubicin—thyroid cancer	0.000241	0.0022	CcSEcCtD
Lidocaine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00024	0.00219	CcSEcCtD
Lidocaine—Angiopathy—Epirubicin—thyroid cancer	0.000237	0.00216	CcSEcCtD
Lidocaine—Immune system disorder—Epirubicin—thyroid cancer	0.000235	0.00215	CcSEcCtD
Lidocaine—Chills—Epirubicin—thyroid cancer	0.000234	0.00214	CcSEcCtD
Lidocaine—Visual impairment—Doxorubicin—thyroid cancer	0.000232	0.00212	CcSEcCtD
Lidocaine—Erythema—Epirubicin—thyroid cancer	0.000227	0.00207	CcSEcCtD
Lidocaine—Eye disorder—Doxorubicin—thyroid cancer	0.000225	0.00206	CcSEcCtD
Lidocaine—Tinnitus—Doxorubicin—thyroid cancer	0.000225	0.00206	CcSEcCtD
Lidocaine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000224	0.00205	CcSEcCtD
Lidocaine—Flushing—Doxorubicin—thyroid cancer	0.000224	0.00205	CcSEcCtD
Lidocaine—Tension—Epirubicin—thyroid cancer	0.000223	0.00204	CcSEcCtD
Lidocaine—Dysgeusia—Epirubicin—thyroid cancer	0.000222	0.00203	CcSEcCtD
Lidocaine—Nervousness—Epirubicin—thyroid cancer	0.00022	0.00201	CcSEcCtD
Lidocaine—Back pain—Epirubicin—thyroid cancer	0.00022	0.00201	CcSEcCtD
Lidocaine—Angiopathy—Doxorubicin—thyroid cancer	0.000219	0.002	CcSEcCtD
Lidocaine—Immune system disorder—Doxorubicin—thyroid cancer	0.000218	0.00199	CcSEcCtD
Lidocaine—Chills—Doxorubicin—thyroid cancer	0.000216	0.00198	CcSEcCtD
Lidocaine—Vision blurred—Epirubicin—thyroid cancer	0.000214	0.00195	CcSEcCtD
Lidocaine—Erythema—Doxorubicin—thyroid cancer	0.00021	0.00192	CcSEcCtD
Lidocaine—Agitation—Epirubicin—thyroid cancer	0.000209	0.00191	CcSEcCtD
Lidocaine—Tension—Doxorubicin—thyroid cancer	0.000206	0.00188	CcSEcCtD
Lidocaine—Dysgeusia—Doxorubicin—thyroid cancer	0.000206	0.00188	CcSEcCtD
Lidocaine—Nervousness—Doxorubicin—thyroid cancer	0.000204	0.00186	CcSEcCtD
Lidocaine—Back pain—Doxorubicin—thyroid cancer	0.000203	0.00186	CcSEcCtD
Lidocaine—Loss of consciousness—Epirubicin—thyroid cancer	0.000199	0.00182	CcSEcCtD
Lidocaine—Vision blurred—Doxorubicin—thyroid cancer	0.000198	0.00181	CcSEcCtD
Lidocaine—Convulsion—Epirubicin—thyroid cancer	0.000197	0.0018	CcSEcCtD
Lidocaine—Hypertension—Epirubicin—thyroid cancer	0.000196	0.00179	CcSEcCtD
Lidocaine—Chest pain—Epirubicin—thyroid cancer	0.000193	0.00177	CcSEcCtD
Lidocaine—Agitation—Doxorubicin—thyroid cancer	0.000193	0.00176	CcSEcCtD
Lidocaine—Anxiety—Epirubicin—thyroid cancer	0.000193	0.00176	CcSEcCtD
Lidocaine—Confusional state—Epirubicin—thyroid cancer	0.000187	0.00171	CcSEcCtD
Lidocaine—Anaphylactic shock—Epirubicin—thyroid cancer	0.000185	0.00169	CcSEcCtD
Lidocaine—Oedema—Epirubicin—thyroid cancer	0.000185	0.00169	CcSEcCtD
Lidocaine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000185	0.00169	CcSEcCtD
Lidocaine—Shock—Epirubicin—thyroid cancer	0.000182	0.00167	CcSEcCtD
Lidocaine—Convulsion—Doxorubicin—thyroid cancer	0.000182	0.00166	CcSEcCtD
Lidocaine—Nervous system disorder—Epirubicin—thyroid cancer	0.000182	0.00166	CcSEcCtD
Lidocaine—Hypertension—Doxorubicin—thyroid cancer	0.000181	0.00166	CcSEcCtD
Lidocaine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000179	0.00164	CcSEcCtD
Lidocaine—Chest pain—Doxorubicin—thyroid cancer	0.000179	0.00163	CcSEcCtD
Lidocaine—Anxiety—Doxorubicin—thyroid cancer	0.000178	0.00163	CcSEcCtD
Lidocaine—Hypotension—Epirubicin—thyroid cancer	0.000173	0.00158	CcSEcCtD
Lidocaine—Confusional state—Doxorubicin—thyroid cancer	0.000173	0.00158	CcSEcCtD
Lidocaine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000171	0.00157	CcSEcCtD
Lidocaine—Oedema—Doxorubicin—thyroid cancer	0.000171	0.00157	CcSEcCtD
Lidocaine—Shock—Doxorubicin—thyroid cancer	0.000169	0.00154	CcSEcCtD
Lidocaine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000168	0.00154	CcSEcCtD
Lidocaine—Paraesthesia—Epirubicin—thyroid cancer	0.000166	0.00152	CcSEcCtD
Lidocaine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000166	0.00151	CcSEcCtD
Lidocaine—Dyspnoea—Epirubicin—thyroid cancer	0.000165	0.00151	CcSEcCtD
Lidocaine—Somnolence—Epirubicin—thyroid cancer	0.000165	0.0015	CcSEcCtD
Lidocaine—Hypotension—Doxorubicin—thyroid cancer	0.00016	0.00146	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00016	0.00146	CcSEcCtD
Lidocaine—Pain—Epirubicin—thyroid cancer	0.000158	0.00145	CcSEcCtD
Lidocaine—Paraesthesia—Doxorubicin—thyroid cancer	0.000154	0.00141	CcSEcCtD
Lidocaine—Dyspnoea—Doxorubicin—thyroid cancer	0.000153	0.0014	CcSEcCtD
Lidocaine—Feeling abnormal—Epirubicin—thyroid cancer	0.000153	0.00139	CcSEcCtD
Lidocaine—Somnolence—Doxorubicin—thyroid cancer	0.000152	0.00139	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000148	0.00135	CcSEcCtD
Lidocaine—Urticaria—Epirubicin—thyroid cancer	0.000147	0.00134	CcSEcCtD
Lidocaine—Pain—Doxorubicin—thyroid cancer	0.000147	0.00134	CcSEcCtD
Lidocaine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000141	0.00129	CcSEcCtD
Lidocaine—Hypersensitivity—Epirubicin—thyroid cancer	0.000136	0.00125	CcSEcCtD
Lidocaine—Urticaria—Doxorubicin—thyroid cancer	0.000136	0.00124	CcSEcCtD
Lidocaine—Asthenia—Epirubicin—thyroid cancer	0.000133	0.00121	CcSEcCtD
Lidocaine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000126	0.00115	CcSEcCtD
Lidocaine—Asthenia—Doxorubicin—thyroid cancer	0.000123	0.00112	CcSEcCtD
Lidocaine—Dizziness—Epirubicin—thyroid cancer	0.000122	0.00112	CcSEcCtD
Lidocaine—Vomiting—Epirubicin—thyroid cancer	0.000118	0.00108	CcSEcCtD
Lidocaine—Rash—Epirubicin—thyroid cancer	0.000117	0.00107	CcSEcCtD
Lidocaine—Dermatitis—Epirubicin—thyroid cancer	0.000117	0.00107	CcSEcCtD
Lidocaine—Headache—Epirubicin—thyroid cancer	0.000116	0.00106	CcSEcCtD
Lidocaine—Dizziness—Doxorubicin—thyroid cancer	0.000113	0.00104	CcSEcCtD
Lidocaine—Nausea—Epirubicin—thyroid cancer	0.00011	0.00101	CcSEcCtD
Lidocaine—Vomiting—Doxorubicin—thyroid cancer	0.000109	0.000996	CcSEcCtD
Lidocaine—Rash—Doxorubicin—thyroid cancer	0.000108	0.000987	CcSEcCtD
Lidocaine—Dermatitis—Doxorubicin—thyroid cancer	0.000108	0.000987	CcSEcCtD
Lidocaine—Headache—Doxorubicin—thyroid cancer	0.000107	0.000981	CcSEcCtD
Lidocaine—Nausea—Doxorubicin—thyroid cancer	0.000102	0.00093	CcSEcCtD
Lidocaine—EGFR—Signaling by GPCR—SST—thyroid cancer	4.17e-05	0.000545	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—HRAS—thyroid cancer	4.15e-05	0.000543	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—HRAS—thyroid cancer	4.15e-05	0.000543	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	4.14e-05	0.000541	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—HRAS—thyroid cancer	4.13e-05	0.00054	CbGpPWpGaD
Lidocaine—EGFR—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	4.13e-05	0.00054	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CHST14—thyroid cancer	4.13e-05	0.00054	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—MINPP1—thyroid cancer	4.12e-05	0.000539	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—HRAS—thyroid cancer	4.11e-05	0.000538	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—NDUFA13—thyroid cancer	4.1e-05	0.000537	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—HRAS—thyroid cancer	4.09e-05	0.000535	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	4.08e-05	0.000534	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	4.08e-05	0.000534	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—AKT1—thyroid cancer	4.08e-05	0.000533	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—thyroid cancer	4.03e-05	0.000527	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—PTEN—thyroid cancer	4.02e-05	0.000525	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	4.02e-05	0.000525	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CALCA—thyroid cancer	4.01e-05	0.000525	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	4.01e-05	0.000525	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—HRAS—thyroid cancer	3.97e-05	0.000519	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—SLC5A5—thyroid cancer	3.95e-05	0.000516	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—AKT1—thyroid cancer	3.9e-05	0.00051	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CHST14—thyroid cancer	3.89e-05	0.000509	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	3.88e-05	0.000507	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	3.86e-05	0.000505	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CHST14—thyroid cancer	3.86e-05	0.000505	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	3.85e-05	0.000503	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—HRAS—thyroid cancer	3.85e-05	0.000503	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—HRAS—thyroid cancer	3.85e-05	0.000503	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—AKT1—thyroid cancer	3.84e-05	0.000502	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—HPGD—thyroid cancer	3.82e-05	0.0005	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—HRAS—thyroid cancer	3.82e-05	0.000499	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—HRAS—thyroid cancer	3.82e-05	0.000499	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—HRAS—thyroid cancer	3.82e-05	0.000499	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	3.79e-05	0.000495	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—PPARG—thyroid cancer	3.78e-05	0.000495	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—HRAS—thyroid cancer	3.78e-05	0.000494	CbGpPWpGaD
Lidocaine—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	3.78e-05	0.000494	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—HRAS—thyroid cancer	3.77e-05	0.000492	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—HRAS—thyroid cancer	3.68e-05	0.000481	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—AKT1—thyroid cancer	3.67e-05	0.000479	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—AKT1—thyroid cancer	3.67e-05	0.000479	CbGpPWpGaD
Lidocaine—EGFR—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	3.65e-05	0.000477	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—AKT1—thyroid cancer	3.65e-05	0.000477	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—HRAS—thyroid cancer	3.64e-05	0.000476	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CDK1—thyroid cancer	3.63e-05	0.000475	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—AKT1—thyroid cancer	3.63e-05	0.000475	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—HRAS—thyroid cancer	3.63e-05	0.000474	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—AKT1—thyroid cancer	3.61e-05	0.000472	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—NRAS—thyroid cancer	3.58e-05	0.000469	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—HRAS—thyroid cancer	3.56e-05	0.000466	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	3.56e-05	0.000466	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—AKT1—thyroid cancer	3.54e-05	0.000463	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—NRAS—thyroid cancer	3.54e-05	0.000462	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—AKT1—thyroid cancer	3.51e-05	0.000459	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—NDUFA13—thyroid cancer	3.51e-05	0.000459	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—TPR—thyroid cancer	3.51e-05	0.000458	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	3.45e-05	0.000451	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	3.41e-05	0.000446	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—AKT1—thyroid cancer	3.4e-05	0.000444	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	3.4e-05	0.000444	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—AKT1—thyroid cancer	3.4e-05	0.000444	CbGpPWpGaD
Lidocaine—EGFR—Disease—CALCA—thyroid cancer	3.39e-05	0.000443	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—AKT1—thyroid cancer	3.37e-05	0.000441	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—AKT1—thyroid cancer	3.37e-05	0.000441	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—AKT1—thyroid cancer	3.37e-05	0.000441	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—AKT1—thyroid cancer	3.34e-05	0.000437	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—HPGD—thyroid cancer	3.33e-05	0.000435	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—AKT1—thyroid cancer	3.32e-05	0.000435	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CDK1—thyroid cancer	3.32e-05	0.000434	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—RXRA—thyroid cancer	3.32e-05	0.000434	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CHST14—thyroid cancer	3.3e-05	0.000431	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	3.3e-05	0.000431	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—AKT1—thyroid cancer	3.25e-05	0.000425	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—NRAS—thyroid cancer	3.24e-05	0.000424	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—TPR—thyroid cancer	3.21e-05	0.00042	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	3.21e-05	0.00042	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—AKT1—thyroid cancer	3.21e-05	0.00042	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	3.2e-05	0.000418	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IFNA2—thyroid cancer	3.19e-05	0.000418	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—MINPP1—thyroid cancer	3.18e-05	0.000416	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TSHR—thyroid cancer	3.17e-05	0.000414	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PRKAR1A—thyroid cancer	3.16e-05	0.000413	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—AKT1—thyroid cancer	3.15e-05	0.000411	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—HPGD—thyroid cancer	3.14e-05	0.00041	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PRKAR1A—thyroid cancer	3.12e-05	0.000408	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—HPGD—thyroid cancer	3.11e-05	0.000407	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.1e-05	0.000405	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—KRAS—thyroid cancer	3.09e-05	0.000403	CbGpPWpGaD
Lidocaine—EGFR—Disease—CDK1—thyroid cancer	3.07e-05	0.000401	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.06e-05	0.0004	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—KRAS—thyroid cancer	3.04e-05	0.000398	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	3.01e-05	0.000394	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MEN1—thyroid cancer	2.98e-05	0.000389	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	2.9e-05	0.00038	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.8e-05	0.000366	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—KRAS—thyroid cancer	2.79e-05	0.000365	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.71e-05	0.000354	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTCH1—thyroid cancer	2.69e-05	0.000352	CbGpPWpGaD
Lidocaine—EGFR—Immune System—NRG1—thyroid cancer	2.66e-05	0.000348	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—HPGD—thyroid cancer	2.66e-05	0.000348	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—SLC5A5—thyroid cancer	2.62e-05	0.000343	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—HRAS—thyroid cancer	2.62e-05	0.000343	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—TPR—thyroid cancer	2.59e-05	0.000339	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—HRAS—thyroid cancer	2.59e-05	0.000338	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.57e-05	0.000336	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PRKAR1A—thyroid cancer	2.55e-05	0.000334	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CHST14—thyroid cancer	2.54e-05	0.000333	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—TPR—thyroid cancer	2.53e-05	0.000331	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.52e-05	0.00033	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	2.49e-05	0.000326	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SST—thyroid cancer	2.46e-05	0.000322	CbGpPWpGaD
Lidocaine—EGFR—Disease—NRG1—thyroid cancer	2.46e-05	0.000322	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—SLC5A5—thyroid cancer	2.41e-05	0.000315	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—HRAS—thyroid cancer	2.37e-05	0.00031	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CALCA—thyroid cancer	2.37e-05	0.00031	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—AKT1—thyroid cancer	2.32e-05	0.000303	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—NRAS—thyroid cancer	2.32e-05	0.000303	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—PTEN—thyroid cancer	2.29e-05	0.0003	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—AKT1—thyroid cancer	2.28e-05	0.000299	CbGpPWpGaD
Lidocaine—EGFR—Disease—TERT—thyroid cancer	2.21e-05	0.000289	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—RXRA—thyroid cancer	2.2e-05	0.000288	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—PTEN—thyroid cancer	2.2e-05	0.000288	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—TPR—thyroid cancer	2.19e-05	0.000287	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	2.16e-05	0.000282	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.16e-05	0.000282	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.15e-05	0.000281	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CDK1—thyroid cancer	2.15e-05	0.000281	CbGpPWpGaD
Lidocaine—EGFR—Disease—HIF1A—thyroid cancer	2.11e-05	0.000276	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PPARG—thyroid cancer	2.09e-05	0.000274	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—HPGD—thyroid cancer	2.05e-05	0.000268	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—NRAS—thyroid cancer	2.04e-05	0.000267	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—RXRA—thyroid cancer	2.02e-05	0.000264	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—KRAS—thyroid cancer	1.99e-05	0.000261	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—NRAS—thyroid cancer	1.96e-05	0.000257	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.96e-05	0.000256	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—SLC5A5—thyroid cancer	1.94e-05	0.000254	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—TPR—thyroid cancer	1.91e-05	0.00025	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.91e-05	0.00025	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—SLC5A5—thyroid cancer	1.9e-05	0.000248	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.88e-05	0.000246	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—TPR—thyroid cancer	1.8e-05	0.000236	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—TPR—thyroid cancer	1.79e-05	0.000234	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.77e-05	0.000232	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—KRAS—thyroid cancer	1.76e-05	0.00023	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	1.76e-05	0.00023	CbGpPWpGaD
Lidocaine—EGFR—Disease—BRAF—thyroid cancer	1.75e-05	0.000229	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NRG1—thyroid cancer	1.72e-05	0.000225	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—HRAS—thyroid cancer	1.69e-05	0.000221	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—KRAS—thyroid cancer	1.69e-05	0.000221	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTGS2—thyroid cancer	1.65e-05	0.000215	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.64e-05	0.000215	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—RXRA—thyroid cancer	1.63e-05	0.000213	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.61e-05	0.000211	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—RXRA—thyroid cancer	1.59e-05	0.000208	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.59e-05	0.000208	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TERT—thyroid cancer	1.55e-05	0.000202	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.54e-05	0.000201	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—TPR—thyroid cancer	1.53e-05	0.0002	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.5e-05	0.000196	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—HRAS—thyroid cancer	1.5e-05	0.000196	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—AKT1—thyroid cancer	1.5e-05	0.000196	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HIF1A—thyroid cancer	1.48e-05	0.000193	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTEN—thyroid cancer	1.44e-05	0.000188	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HRAS—thyroid cancer	1.44e-05	0.000188	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.43e-05	0.000187	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTGS2—thyroid cancer	1.41e-05	0.000185	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PPARG—thyroid cancer	1.39e-05	0.000182	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—RXRA—thyroid cancer	1.38e-05	0.000181	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.36e-05	0.000178	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.35e-05	0.000176	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.34e-05	0.000176	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.34e-05	0.000175	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PTEN—thyroid cancer	1.33e-05	0.000175	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—AKT1—thyroid cancer	1.32e-05	0.000173	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—NRAS—thyroid cancer	1.3e-05	0.00017	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PPARG—thyroid cancer	1.28e-05	0.000167	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—AKT1—thyroid cancer	1.27e-05	0.000166	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.25e-05	0.000164	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTEN—thyroid cancer	1.23e-05	0.000161	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—BRAF—thyroid cancer	1.23e-05	0.00016	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—RXRA—thyroid cancer	1.2e-05	0.000157	CbGpPWpGaD
Lidocaine—EGFR—Immune System—NRAS—thyroid cancer	1.19e-05	0.000156	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—TPR—thyroid cancer	1.18e-05	0.000154	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.16e-05	0.000152	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.14e-05	0.000149	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—RXRA—thyroid cancer	1.13e-05	0.000148	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—RXRA—thyroid cancer	1.12e-05	0.000147	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—KRAS—thyroid cancer	1.12e-05	0.000147	CbGpPWpGaD
Lidocaine—EGFR—Disease—NRAS—thyroid cancer	1.1e-05	0.000144	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTGS2—thyroid cancer	1.1e-05	0.000143	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.09e-05	0.000143	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.07e-05	0.00014	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PPARG—thyroid cancer	1.03e-05	0.000135	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KRAS—thyroid cancer	1.02e-05	0.000134	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PPARG—thyroid cancer	1.01e-05	0.000132	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTGS2—thyroid cancer	1e-05	0.000131	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—RXRA—thyroid cancer	9.6e-06	0.000126	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTEN—thyroid cancer	9.55e-06	0.000125	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—HRAS—thyroid cancer	9.54e-06	0.000125	CbGpPWpGaD
Lidocaine—EGFR—Disease—KRAS—thyroid cancer	9.46e-06	0.000124	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	9.34e-06	0.000122	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCND1—thyroid cancer	8.94e-06	0.000117	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	8.82e-06	0.000115	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTEN—thyroid cancer	8.75e-06	0.000114	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PPARG—thyroid cancer	8.72e-06	0.000114	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HRAS—thyroid cancer	8.71e-06	0.000114	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTEN—thyroid cancer	8.63e-06	0.000113	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—AKT1—thyroid cancer	8.42e-06	0.00011	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—AKT1—thyroid cancer	8.28e-06	0.000108	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS2—thyroid cancer	8.1e-06	0.000106	CbGpPWpGaD
Lidocaine—EGFR—Disease—HRAS—thyroid cancer	8.04e-06	0.000105	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS2—thyroid cancer	7.92e-06	0.000104	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NRAS—thyroid cancer	7.7e-06	0.000101	CbGpPWpGaD
Lidocaine—EGFR—Immune System—AKT1—thyroid cancer	7.69e-06	0.000101	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PPARG—thyroid cancer	7.59e-06	9.93e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—RXRA—thyroid cancer	7.41e-06	9.69e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PPARG—thyroid cancer	7.16e-06	9.36e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—AKT1—thyroid cancer	7.1e-06	9.29e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PPARG—thyroid cancer	7.09e-06	9.28e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTEN—thyroid cancer	7.06e-06	9.24e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTEN—thyroid cancer	6.9e-06	9.03e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS2—thyroid cancer	6.86e-06	8.97e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KRAS—thyroid cancer	6.63e-06	8.67e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PPARG—thyroid cancer	6.06e-06	7.93e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTEN—thyroid cancer	5.98e-06	7.82e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS2—thyroid cancer	5.97e-06	7.81e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—thyroid cancer	5.89e-06	7.7e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HRAS—thyroid cancer	5.63e-06	7.37e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS2—thyroid cancer	5.63e-06	7.36e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS2—thyroid cancer	5.58e-06	7.3e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—AKT1—thyroid cancer	5.5e-06	7.2e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTEN—thyroid cancer	5.21e-06	6.81e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—AKT1—thyroid cancer	5.05e-06	6.6e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AKT1—thyroid cancer	4.97e-06	6.5e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTEN—thyroid cancer	4.91e-06	6.42e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTEN—thyroid cancer	4.87e-06	6.36e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS2—thyroid cancer	4.77e-06	6.24e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPARG—thyroid cancer	4.68e-06	6.12e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTEN—thyroid cancer	4.16e-06	5.44e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—AKT1—thyroid cancer	4.07e-06	5.32e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—AKT1—thyroid cancer	3.98e-06	5.2e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.68e-06	4.81e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—AKT1—thyroid cancer	3.45e-06	4.51e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTEN—thyroid cancer	3.21e-06	4.2e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—AKT1—thyroid cancer	3e-06	3.93e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—AKT1—thyroid cancer	2.83e-06	3.7e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—AKT1—thyroid cancer	2.8e-06	3.67e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—AKT1—thyroid cancer	2.4e-06	3.13e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—AKT1—thyroid cancer	1.85e-06	2.42e-05	CbGpPWpGaD
